Bristol Myers Squibb Co., in a lawsuit made public on March 17, said AstraZeneca’s cancer treatment Imfinzi violates patents related to the company’s blockbuster cancer drug Opdivo.
Merck announced that the company’s proposed treatment Keytruda for non-small cell lung cancer delivered positive results from a Phase III trial.
Pfizer Halts Business in Russia, Suggests 4th Booster is Necessary
BNT162b2 (Pfizer and BioNTech), Business, Clinical Trials, CNN, Collaborations, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, Drug Supply Chain, Face The Nation, FDA, Hepatocellular Carcinoma, Humanitarian support, Non-Small Cell Lung Cancer, Pfizer, R&D, Russia, Therapeutics, Tumors, UkraineIn response to the ongoing Russian invasion of Ukraine, Pfizer will cease operations within Russia and proceeds from the company’s subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine. Regarding COVID-19, Pfizer Chief Executive Officer Albert Bourla noted in an interview with Face the Nation that it is likely that a fourth booster shot of the company’s vaccine will be needed to fend off another surge of infections.
The U.S. Food and Drug Administration approved the expanded use of Bristol Myers Squibb’s cancer drug Opdivo along with chemotherapy as treatment that patients with an aggressive form of lung cancer receive before surgery.
Amgen Chairman and Chief Executive Officer Robert Bradway anticipates the non-small cell lung cancer drug Lumakras will become a cornerstone medicine as the company aims to develop multiple medications for targets long thought to be undruggable.
Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.
Lung Cancer Breakthroughs Touted at ESMO 2021
AstraZeneca, Clinical Data, Clinical Trials, Daiichi Sankyo, EGFR tyrosine kinase inhibitors (TKI), European Society for Medical Oncology (ESMO), Janssen, KRAS Mutations, Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-Based Chemotherapy, R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Topline DataCompanies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.
Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.
Takeda’s Exkivity Approved by U.S. FDA as First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
Adults, Approvals, Clinical Trials, EGFR exon 20 insertion mutations, FDA, Metastatic non-small cell lung cancer, Next-Generation Sequencing (NGS), Platinum-Based Chemotherapy, R&D, Takeda, TherapeuticsThe U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
The United States Food and Drugs Administration granted a priority review for Roche’s Tecentriq treatment for people suffering with early, non-small-cell lung cancer, the Swiss company said on Aug. 3.